OPL

Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 9, 2023
Stem Cells, Biotechnology, Pharmaceutical, Optical, Oncology, Health, Health Technology, Clinical Trials, Webcast, RPE, Interest, B2M, Research, VAC, D, Therapy, Visual acuity, OCT, IND, Lineage Cell Therapeutics, Eterna, INL, Patient, FDA, Collaboration, G&A, OPL, Expense, Investigational New Drug, NYSE American, Trial of the century, ELM, AMD, Geographic atrophy, Roche, Survival, Partnership, Congress, Letter, TASE, NK, Pharmaceutical industry, Fine chemical, Vaccine, Genentech

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the third quarter ended September 30, 2023 and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the third quarter ended September 30, 2023 and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.
  • “The Lineage team has continued to advance our clinical and preclinical pipeline of differentiated cell transplant programs, supporting our alliances and working to establish new collaborations,” stated Brian M. Culley, Lineage CEO.
  • Interested parties may access today’s conference call and webcast, by dialing (800) 715-9871 from the U.S. and Canada and should request the “Lineage Cell Therapeutics Call”.
  • A live webcast of the conference call will be available online in the Investors section of Lineage’s website.

RG6501 (OpRegen®) Phase 1/2a Results Show Evidence of Rapid Improvement of Outer Retinal Structure in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Retrieved on: 
Thursday, October 5, 2023
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Congress, Lineage Cell Therapeutics, Tel Aviv Sourasky Medical Center, Letter, Trial of the century, Cell, Maintenance, OPL, OCT, Therapy, AMD, NYSE American, GA, INL, TASE, RPE, Patient, Geographic atrophy, ELM, Fine chemical, Medical imaging, Genentech, Ophthalmology, Lineage

RG6501 (OpRegen) is a suspension of human allogeneic retinal pigmented epithelial (RPE) cells currently in development for the treatment of GA secondary to age-related macular degeneration (AMD).

Key Points: 
  • RG6501 (OpRegen) is a suspension of human allogeneic retinal pigmented epithelial (RPE) cells currently in development for the treatment of GA secondary to age-related macular degeneration (AMD).
  • OpRegen subretinal delivery has the potential to counteract RPE cell loss in areas of GA lesions by supporting retinal cell health and improving retinal structure and function.
  • “We are extremely pleased to see these additional observations of rapid improvements to outer retinal structure in the initial clinical study of OpRegen.
  • Durability of retinal structure improvements beyond the 12-month primary endpoint is still being evaluated in other patients.

Lockheed Martin Skunk Works® and University of Iowa Successfully Demonstrate Artificial Intelligence-Commanded Mission

Retrieved on: 
Monday, September 11, 2023
Aircraft, Lockheed Martin, Altitude, University, UAS, University of Iowa, Air Force Test Center, Code, CCA, Lockheed, Behavior, Skunk Works, IOWA, DOD, Radar, Century, Artificial intelligence, Air force, AI, Environment, OPL, NYSE, L-29, LMT, D, Medical device

This project, named Enhanced Collaborative High-Frequency Orientation System (ECHOS), was sponsored by Lockheed Martin's 21st Century Security Demonstrations & Prototypes (D&P) organization.

Key Points: 
  • This project, named Enhanced Collaborative High-Frequency Orientation System (ECHOS), was sponsored by Lockheed Martin's 21st Century Security Demonstrations & Prototypes (D&P) organization.
  • The L-29s were flown by experienced OPL pilots, following instructions from the AI agents in the form of heading, altitude, and speed cues.
  • Demonstrating how AI can provide data for rapid decision making and increased mission effectiveness by reducing pilot workload.
  • Agents were able to learn these tactics with sparse rewards, ensuring the best possible tactics for the mission were executed.

NUZEST USA Wins Best Superfood Supplement Award With Its Good Green Vitality Product

Retrieved on: 
Wednesday, May 31, 2023
Cognition, Mineral, Diet, Sugar, Ageing, Nutrient, Vegetable, Inflammation, USD, Disorder, Vitamin, Dietary supplement, Risk, Immune system, Growth, Research, OPL, Allergen, Vitality, Antioxidant, International Journal of Research in Marketing

NEW YORK, May 31, 2023 /PRNewswire/ -- Nutritional supplement pioneer NUZEST's Good Green Vitality has been named "Best Superfood" by Optimal Performance Living (OPL). The product is being recognized for its carefully formulated protein superfood blend of beneficial ingredients, which work synergistically to improve immune system functionality, reduce stress and inflammation, and enhance cognition — all in a single daily serving. [See full press release.]

Key Points: 
  • NUZEST USA, a fast-growing industry-leading supplier of plant-protein-based nutrition products and dietary supplements, has won an award for its internationally acclaimed Good Green Vitality superfood product.
  • NEW YORK, May 31, 2023 /PRNewswire/ -- Nutritional supplement pioneer NUZEST's Good Green Vitality has been named "Best Superfood" by Optimal Performance Living (OPL).
  • Good Green Vitality is suitable for people of all ages and is especially recommended for those who want to slow the aging process.
  • Good Green Vitality undergoes independent third-party testing to ensure there are no added sugars, fillers, preservatives, gluten, dairy, soy, or other allergens.

EVI Industries Reports Record Results for Second Quarter of Fiscal 2023

Retrieved on: 
Thursday, February 9, 2023
Other Construction & Property, Manufacturing, Commercial Building & Real Estate, Construction & Property, Building Systems, Other Manufacturing, Record, Earnings before interest, taxes, depreciation and amortization, Investment, Tax, Cyprus Securities and Exchange Commission, Security (finance), NYSE, Acquisition, Maintenance, Compensation, EBITDA, Courage, GAAP, OPL, WCL, Intelligence, Adjustment, EVI, Growth, Interest, Collection, Cryptocurrency, Renewable energy, Reinsurance, Bookkeeping, Depreciation

EVI Industries, Inc. (NYSE American: EVI) (“EVI” or the “Company”) announced record results in key performance measures for the three and six months ended December 31, 2022, and provided commentary on growth initiatives, technology deployments, and financial strength.

Key Points: 
  • EVI Industries, Inc. (NYSE American: EVI) (“EVI” or the “Company”) announced record results in key performance measures for the three and six months ended December 31, 2022, and provided commentary on growth initiatives, technology deployments, and financial strength.
  • Henry M. Nahmad, EVI’s Chairman and CEO commented: “EVI is a collection of ambitious people, bound by an entrepreneurial culture and core values, focused on winning.
  • This revenue performance resulted in record net income and adjusted EBITDA, including record adjusted EBITDA margin of 7.2% and 7.5% for the three and six-month periods ended December 31, 2022, respectively.
  • In this press release, EVI discloses the non-GAAP financial measure of Adjusted EBITDA, which EVI defines as earnings before interest, taxes, depreciation, amortization, and amortization of share-based compensation.

3.5 Million Viewers Watched "On Patrol: Live" Over the Weekend

Retrieved on: 
Wednesday, July 27, 2022
COPS, AT&T, DIRECTV, Autopsy, Tubi, Pluto TV, Three's Company, Network, Crackle, CEO, Lists of television programs, Cable, AT, MSU, SAT, Amazon Fire TV, Drama, Kennedy family, Verizon Fios, Television, Smart TV, Vizio, Music, Mao: The Unknown Story, Reload, OPL, Company, Gangster, Week, Dish Network, Redbox, Roku, Program, Samsung, Nightclub, Xfinity, Spectrum, HD

ALBUQUERQUE, N.M., July 27, 2022 /PRNewswire-PRWeb/ -- REELZ today announced that 3.5 million unique viewers watched "On Patrol: Live" with an average viewing time of 146 minutes across the seven telecasts over the premiere weekend starting Friday, July 22. The huge audience turnout for "On Patrol: Live" made it the #1 most watched show on cable among adults 25-54 on Friday and Saturday night.

Key Points: 
  • The huge audience turnout for "On Patrol: Live" made it the #1 most watched show on cable among adults 25-54 on Friday and Saturday night.
  • "On Patrol: Live" on Saturday night attracted an even larger audience from 9pm-12am averaging 403,000 among A25-54, also making the show the most watched on cable that night.
  • The strong performance of the "On Patrol: Live" premiere weekend propelled REELZ into a top 25 cable network position for the first time ever.
  • Nielsen Power Reach & Frequency for seven OPL telecasts during premiere weekend based on Live+SD stream, 6 minute cume qualifier.